Navigation Links
Labopharm to host webcast presentation on novel trazodone formulation for treatment of major depressive disorder
Date:11/24/2008

e of sexual dysfunction and no weight gain compared to placebo.

MDD is one of the most prevalent central nervous system disorders, affecting more than 120 million people worldwide. In 2007, the global market for antidepressants and related psychiatric drugs was US$19 billion, of which US$12 billion was accounted for by the U.S.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally and its second product, a novel formulation of trazodone for the treatment of major depressive disorder, is under regulatory review by the FDA. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit www.labopharm.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the uncertainties related to the regulatory process in various countries for the approval of the Company's products and the successful commercialization of the products throughout the world if they are approved. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking stat
'/>"/>

SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... New York (PRWEB) August 21, 2014 ... Market Research “Home Audio Equipment (Product Types - Home ... audio accessories) Market - Global Industry Analysis, Size, Share, ... was valued at USD 15.94 billion in 2012 and ... growing at a CAGR of 3.7% from 2013 to ...
(Date:8/21/2014)... 21, 2014 The Swedish-American Life ... conference will focus on the Future of Medicine ... innovation and commercialization. , With the mission to ... the worlds' of business and science. "Over the ... Summit, gathering a diverse community with representatives challenging ...
(Date:8/21/2014)... HealthDay Reporter THURSDAY, Aug. ... using sunscreen dropped nearly 12 percent in the last decade, ... the number of teens using indoor tanning beds barely decreased. ... risk of skin cancers, including deadly melanomas, the researchers noted. ... of teens who reported wearing sunscreen, from 67.7 percent in ...
(Date:8/21/2014)... August 21, 2014 The Onder Law ... product liability law, announces the launch of a new ... information on morcellator surgery lawsuits for cancer ... morcellator cancer warning and the July 2014 morcellator recall. ... April 17, 2014 FDA warning on morcellator surgery and ...
(Date:8/21/2014)... announces the immediate release of Care of the ... CHEST Consensus Statement today in the Online First ... the global health-care community cares for patients with ... guide ethical decision-making, coordination of care, resource conservation, ... by over 100 clinicians and experts representing a ...
Breaking Medicine News(10 mins):Health News:Home Audio Equipment Market Expected to Reach USD 20.68 Billion in 2019 2Health News:Home Audio Equipment Market Expected to Reach USD 20.68 Billion in 2019 3Health News:The Tenth Swedish-American Life Science Summit, takingplace in Stockholm, Sweden, August 20-22nd, will focus on The Future of Medicine 2Health News:Fewer U.S. Teens Using Sunscreen, Study Finds 2Health News:The Onder Law Firm Launches National Morcellator Cancer Lawsuit Center Website for Morcellator Surgery Lawsuits at MorcellatorCancerLawsuitCenter.com 2Health News:The Onder Law Firm Launches National Morcellator Cancer Lawsuit Center Website for Morcellator Surgery Lawsuits at MorcellatorCancerLawsuitCenter.com 3Health News:CHEST releases new expert guidance in care of the critically ill and injured 2
... reporting successful application of the technology used in home ... make anticancer drugs like tamoxifen and paclitaxel dissolve more ... the disease. The process, described in ACS, journal, Langmuir, ... has potential for improving the performance of dyes, paints, ...
... PITTSBURGHUniversity of Pittsburgh researchers have recorded neuron activity ... biological root of the teenage propensity to consider ... more vulnerable to drug addiction, behavioral disorders, and ... the Journal of Neuroscience that electrode ...
... low socioeconomic status (SES) is associated with higher ... arthritis (RA). Statistically significant differences in race, public ... between depressed and non-depressed patients. Study findings are ... Care & Research , a journal published by ...
... 26 (HealthDay News) -- Hispanic seniors in the United ... be vaccinated against flu and pneumonia, a new study ... analyzed data from more than 244,000 seniors who took ... lifetime immunization rates for pneumonia were 74 percent for ...
... Staphylococcus aureus , the bacterium which is responsible for ... a strategy of hiding within host cells to escape ... The research, published by EMBO Molecular Medicine , ... their environmental conditions, lie dormant inside host cells and ...
... to 20 per cent of nurses and nursing students may ... tackling this difficult issue - and protecting public safety - ... message in a paper in the February issue of the ... recommended six key points that could be built into alternative-to-dismissal ...
Cached Medicine News:Health News:Pitt team finds teen brains over-process rewards, suggesting root of risky behavior, mental ills 2Health News:Low socioeconomic status increases depression risk in rheumatoid arthritis patients 2Health News:Research shows how pathogenic bacteria hide inside host cells 2Health News:Support not punishment is the key to tackling substance abuse and addiction among nurses 2Health News:Support not punishment is the key to tackling substance abuse and addiction among nurses 3
(Date:8/21/2014)... 21, 2014  Vermillion, Inc. (NASDAQ: VRML ... and women,s health, has appointed Holly B. Bauzon ... Ms. Bauzon has a proven track record ... for laboratory services companies. She has more than 20 ... where she held the position of Director, Lab Services ...
(Date:8/21/2014)... YORK , Aug. 21, 2014  Publicis Groupe ... Shannon Hartley , Managing Partner and Healthcare Industry Group ... PharmaVoice 100, which recognizes the most inspiring people in ... are leaders in research and development, marketing, technology, creativity, ... agency in 2006 as a partner in its leading ...
(Date:8/21/2014)... , Aug. 21, 2014 /PRNewswire-iReach/ -- ... Equipment, Inc. for the third straight year, No. ... 500|5000, an exclusive ranking of the nation,s fastest-growing ... look at the most important segment of the ... Timberland, Dell, Domino,s Pizza, LinkedIn, Zillow, and many ...
Breaking Medicine Technology:Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2Shannon Hartley Shines in PharmaVOICE 100 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3
... Development, LLC (JRD) announced today that the U.S. Food ... designation to the supplemental New Drug Application (sNDA) filed ... an oral anticoagulant, to reduce the risk of thrombotic ... The FDA grants Priority Review to medicines ...
... Feb. 27, 2012 With cold and flu season ... American Pharmacists Association (APhA) encourages patients to actively ... medications. Pharmacists are the most accessible health care provider ... best over-the-counter (OTC) medication for cold, flu and allergy ...
Cached Medicine Technology:U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 2U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 3U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 4U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 5U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 6U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 7U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome 8Cold, Flu and Allergy Sufferers Can Select the Best Over-the-Counter Medications with Help from Pharmacists 2Cold, Flu and Allergy Sufferers Can Select the Best Over-the-Counter Medications with Help from Pharmacists 3Cold, Flu and Allergy Sufferers Can Select the Best Over-the-Counter Medications with Help from Pharmacists 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: